曲美他嗪在糖尿病合并严重冠心病患者18F-FDG PET心肌代谢显像中的可行性与应用:前瞻性自身对照研究
本研究以糖尿病合并严重冠心病症状患者为自身对照,探讨口服曲美他嗪对18F-FDG PET心肌代谢显像图像质量、心肌存活评估及定量参数的影响。结果显示,曲美他嗪后图像质量显著改善,心肌SUV和心肌/血池SUV比值(M/B比值)显著升高,检测到的存活心肌节段数和不匹配评分显著增加。
要点
- 曲美他嗪可显著提高糖尿病合并严重冠心病患者18F-FDG PET心肌代谢显像的图像质量。
- 曲美他嗪后心肌SUV和M/B比值显著高于用药前(P均<0.01)。
- 曲美他嗪后检测到的存活心肌节段数和不匹配评分显著增加(P<0.05)。
核心结论
- 曲美他嗪在糖尿病合并严重冠心病患者进行18F-FDG PET心肌代谢显像前使用是可行且有效的,可显著改善图像质量并增加检测到的存活心肌节段数。
研究设计与样本
- 前瞻性自身对照研究,纳入糖尿病合并严重冠心病症状患者作为自身对照,比较曲美他嗪使用前后PET心肌代谢显像的图像质量、心肌存活评估、定量分析参数及不同心肌节段的18F-FDG摄取。
主要发现
- 曲美他嗪后图像质量分级为好、中等、不可判读的患者分别为14例(60.9%)、8例(34.8%)、1例(4.3%),未用曲美他嗪时分别为4例(17.4%)、15例(65.2%)、4例(17.4%)。
- 曲美他嗪后心肌SUV显著高于用药前(3.11 ± 1.07 vs 2.32 ± 1.00,P < 0.01)。
- 曲美他嗪后心肌/血池SUV比值(M/B比值)显著高于用药前(2.67 ± 1.41 vs 1.81 ± 0.75,P < 0.01)。
- 曲美他嗪后检测到6(3, 7)个存活心肌节段,不匹配评分为10(6, 17),显著高于用药前的5(2, 7)个和8(2, 17)(P < 0.05)。
- 灌注减低和灌注正常心肌节段的18F-FDG摄取在曲美他嗪后出现不同范围的增加(增加15.30%-57.77%)。
关键数值与推荐
- 图像质量视觉分级为好、中等、不可判读三级。
- 定量参数包括心肌SUV和心肌/血池SUV比值(M/B比值)。
- 心肌存活评估指标包括存活心肌节段数和不匹配评分。
临床怎么用
- 对糖尿病合并严重冠心病患者,在18F-FDG PET心肌代谢显像前可考虑使用曲美他嗪以改善图像质量并提高存活心肌检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 18F-FDG PET myocardial metabolic imaging (MMI) is sometimes uninterpretable due to background activity from uncontrolled glucose homeostasis in diabetic mellitus (DM) patients. Trimetazidine is an oral medication that promotes the transformation of myocardial energy supply from free fatty acids to glucose. We aimed to investigate the feasibility and application of trimetazidine in 18F-FDG PET MMI of DM patients. METHODS: With DM patients exhibiting severe coronary artery disease (CAD) symptoms serving as self-controls, the effects of trimetazidine on PET MMI image quality, myocardial viability assessment, quantitative analytical parameters, and 18F-FDG uptake of different myocardial segments were elucidated. RESULTS: The image quality of 18F-FDG MMI was graded visually as good, moderate, and uninterpretable. After trimetazidine, grades of good, moderate, and uninterpretable were observed in 14 (60.9%), 8 (34.8%), and 1 (4.3%) patients, respectively, and in 4 (17.4%), 15 (65.2%), 4 (17.4%) patients without trimetazidine. The myocardial SUV and myocardial to blood pool SUV ratio (M/B ratio) were significantly higher after trimetazidine administration than those before (3.11 ± 1.07 vs 2.32 ± 1.00, 2.67 ± 1.41 vs 1.81 ± 0.75, P all < 0.01). 6 (3, 7) viable myocardium segments were detected with a mismatch score of 10 (6, 17) after trimetazidine, significantly higher than those before trimetazidine [5 (2, 7) and 8 (2, 17), P < 0.05]. Meanwhile, the 18F-FDG uptake in myocardial segments with decreased and normal perfusion showed different ranges of increase (by 15.30%-57.77%). CONCLUSION: Trimetazidine is feasible and effective in DM patients with severe CAD before 18F-FDG PET MMI, which can significantly improve the image quality and increase the number of viable myocardium segments detected. TRIAL REGISTRY: The study was registered in the Chinese Clinical Trial Registry (ChiCTR2000038559).
引用
- Shao X, Chen Y, Chen Y, et al. Feasibility and application of trimetazidine in 18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients with severe coronary artery disease: A prospective, self-controlled study. J Nucl Cardiol. 2021. PMID: 34331217. doi:10.1007/s12350-021-02749-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。